These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 15054871

  • 1. Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling.
    Montagna D, Schiavo R, Gibelli N, Pedrazzoli P, Tonelli R, Pagani S, Assirelli E, Locatelli F, Pession A, Fregoni V, Montini E, Da Prada GA, Siena S, Maccario R.
    Int J Cancer; 2004 May 20; 110(1):76-86. PubMed ID: 15054871
    [Abstract] [Full Text] [Related]

  • 2. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I, Pedrazzoli P, Tullio C, Montini E, La Grotteria MC, Schiavo R, Perotti C, Locatelli F, Carretto E, Maccario R, Siena S, Montagna D.
    Cytotherapy; 2007 May 20; 9(5):499-507. PubMed ID: 17786611
    [Abstract] [Full Text] [Related]

  • 3. Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors.
    Montagna D, Maccario R, Montini E, Tonelli R, Lisini D, Pagani S, Comoli P, Moretta A, Assirelli E, Basso S, Vitiello A, Pession A, Locatelli F.
    Exp Hematol; 2003 Nov 20; 31(11):1031-8. PubMed ID: 14585366
    [Abstract] [Full Text] [Related]

  • 4. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S, Wehler T, Schnürer E, Lennerz V, Brenner W, Melchior S, Gröne M, Nonn M, Strand S, Meyer R, Ranieri E, Huber C, Falk CS, Herr W.
    Cancer Res; 2006 Dec 01; 66(23):11447-54. PubMed ID: 17145892
    [Abstract] [Full Text] [Related]

  • 5. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.
    Kurokawa T, Oelke M, Mackensen A.
    Int J Cancer; 2001 Mar 15; 91(6):749-56. PubMed ID: 11275975
    [Abstract] [Full Text] [Related]

  • 6. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P, Micheli L, Vecchio MT, Sabatino M, Petrioli R, Pozzessere D, Marsili S, Giorgi G, Lozzi L, Neri P, Francini G.
    Br J Cancer; 2001 Nov 30; 85(11):1722-30. PubMed ID: 11742494
    [Abstract] [Full Text] [Related]

  • 7. Differential development of CD4 and CD8 cytotoxic T cells (CTL) in PBMC across the leprosy spectrum; IL-6 with IFN-gamma or IL-2 generate CTL in multibacillary patients.
    de la Barrera S, Finiasz DM, Fink S, Valdez R, Bottasso O, Balina LM, Sasiain MC.
    Int J Lepr Other Mycobact Dis; 1997 Mar 30; 65(1):45-55. PubMed ID: 9207753
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation.
    Kurokawa T, Fischer K, Bertz H, Hoegerle S, Finke J, Mackensen A.
    Int J Cancer; 2002 Sep 01; 101(1):52-60. PubMed ID: 12209588
    [Abstract] [Full Text] [Related]

  • 9. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y, Maruyama K, Tai S, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.
    Int J Oncol; 2008 Sep 01; 33(3):433-41. PubMed ID: 18695871
    [Abstract] [Full Text] [Related]

  • 10. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM, Borleri G, Conti E, Ciocca A, Salvi A, Micò C, Introna M, Rambaldi A.
    Exp Hematol; 2006 Apr 01; 34(4):475-85. PubMed ID: 16569594
    [Abstract] [Full Text] [Related]

  • 11. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
    Kass R, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD.
    Breast Cancer Res Treat; 2003 Aug 01; 80(3):275-85. PubMed ID: 14503800
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation.
    Marijt WA, Kernan NA, Diaz-Barrientos T, Veenhof WF, O'Reilly RJ, Willemze R, Falkenburg JH.
    Bone Marrow Transplant; 1995 Jul 01; 16(1):125-32. PubMed ID: 7581111
    [Abstract] [Full Text] [Related]

  • 14. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, Parham GP.
    Am J Obstet Gynecol; 2000 Sep 01; 183(3):601-9. PubMed ID: 10992180
    [Abstract] [Full Text] [Related]

  • 15. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.
    Gervois N, Heuze F, Diez E, Jotereau F.
    Eur J Immunol; 1990 Apr 01; 20(4):825-31. PubMed ID: 1971794
    [Abstract] [Full Text] [Related]

  • 16. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
    Oelke M, Moehrle U, Chen JL, Behringer D, Cerundolo V, Lindemann A, Mackensen A.
    Clin Cancer Res; 2000 May 01; 6(5):1997-2005. PubMed ID: 10815925
    [Abstract] [Full Text] [Related]

  • 17. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2.
    Yamaguchi Y, Ohta K, Shimizu K, Minami K, Noma K, Hihara J, Toge T.
    Anticancer Res; 2001 May 01; 21(1B):669-77. PubMed ID: 11299824
    [Abstract] [Full Text] [Related]

  • 18. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
    Yasumura S, Hirabayashi H, Schwartz DR, Toso JF, Johnson JT, Herberman RB, Whiteside TL.
    Cancer Res; 1993 Mar 15; 53(6):1461-8. PubMed ID: 8443824
    [Abstract] [Full Text] [Related]

  • 19. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J.
    Cell Immunol; 1997 Dec 15; 182(2):137-51. PubMed ID: 9514698
    [Abstract] [Full Text] [Related]

  • 20. Activation of autologous or HLA-identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed with tumor cell extracts.
    Osman Y, Takahashi M, Zheng Z, Toba K, Liu A, Furukawa T, Aizawa Y, Shibata A, Koike T.
    Oncol Rep; 1999 Dec 15; 6(5):1057-63. PubMed ID: 10425303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.